Tesamorelin vs Sermorelin at a glance
- Primary goal
- Tesamorelin: Targeted reduction of visceral adipose tissue (VAT) in the abdomen.
- Sermorelin: Broader GH support for areas like sleep, recovery and body composition under clinical oversight.
- Mechanism
- Both are growth‑hormone releasing hormone (GHRH) analogues that stimulate pituitary GH and raise IGF‑1.
- Tesamorelin has chemical modifications to extend half‑life and has been studied specifically for VAT reduction.
- Evidence and approvals
- Tesamorelin: Randomised trials in HIV‑associated lipodystrophy show clinically meaningful VAT reductions on imaging and improvements in some metabolic markers.
- Sermorelin: Historically used as a diagnostic agent for GH deficiency; adult “wellness” use relies on surrogate markers (IGF‑1) and smaller, less robust evidence.
- Use case fit
- Choose tesamorelin when visceral fat is the clearly defined clinical target.
- Consider sermorelin when the aim is cautious GH-axis support with monitoring.
- Administration
- Both are typically given as daily subcutaneous injections; protocols differ by product and prescriber.
- Common side effects
- Tesamorelin: Injection site reactions, joint pain, tingling, fluid retention, potential glucose effects, IGF‑1 elevation.
- Sermorelin: Flushing, headache, dizziness, injection site irritation, transient changes in IGF‑1.
- Australian access
- Neither is broadly TGA‑approved for general weight loss. Medical access may be possible via a prescribing doctor for specific indications under applicable pathways.
Mechanisms: similar pathway, different emphasis
Tesamorelin and sermorelin both act on GHRH receptors in the pituitary to stimulate pulsatile GH release and downstream IGF‑1. Where they differ is the clinical focus:
- Tesamorelin is a modified GHRH analogue designed to extend activity. Clinical research has centred on decreasing visceral abdominal fat, with changes verified by CT imaging in specific populations.
- Sermorelin is a shorter GHRH(1‑29) analogue. Its contemporary use in adults is often to support GH/IGF‑1 signalling where a clinician identifies low or suboptimal levels or specific symptoms, with careful monitoring.
Results and evidence
Tesamorelin outcomes
- Randomised trials in HIV‑associated lipodystrophy show statistically significant reductions in visceral adipose tissue measured by imaging after several months of use.
- Some studies also note improvements in triglycerides and waist circumference. VAT tends to return toward baseline after discontinuation, so ongoing evaluation is important.
Sermorelin outcomes
- In adults, evidence is more limited and often relies on surrogate endpoints such as increases in IGF‑1 rather than large, long‑term body composition trials.
- Reported goals include sleep quality, recovery, body composition support and general wellbeing under clinical supervision.
For deeper reading, see: Tesamorelin Benefits, Sermorelin Benefits, Tesamorelin for Visceral Fat.
Side effects, risks and monitoring
Safety should be assessed by a prescriber familiar with your history and medications. General considerations include:
- Both medicines elevate IGF‑1; clinicians may monitor IGF‑1 to avoid excessive levels.
- Potential reactions: injection site irritation, fluid shifts, headaches, joint discomfort, flushing or tingling.
- Glucose metabolism: tesamorelin can influence glucose tolerance; metabolic monitoring may be appropriate in at‑risk individuals.
- Contraindications and cautions commonly include active malignancy, pregnancy and breastfeeding, and hypersensitivity to components.
Learn more: Tesamorelin Side Effects, Sermorelin Side Effects, Peptide Side Effects Guide.
Dosing and usage patterns
Both are typically administered as daily subcutaneous injections. Exact protocols, timing and duration vary by indication, product strength and clinician preference. Do not self‑dose; use only under medical supervision.
Details and safety notes: Tesamorelin Dosage Guide and Sermorelin Dosage Guide. If prescribed injections are new to you, see the Peptide Injection Guide.
Which is better for you?
- Choose tesamorelin if your clinician has identified excess visceral abdominal fat as a specific risk and believes a VAT‑targeted approach is warranted.
- Consider sermorelin if the goal is to cautiously support GH/IGF‑1 signalling for issues like sleep, recovery or age‑related decline, with defined targets and monitoring.
Neither medicine replaces foundational lifestyle changes. For general weight loss, GLP‑1‑based therapies may be considered separately under approved indications. See: Weight Loss Injections Australia, GLP‑1 Australia Guide.
Access in Australia: rules and pathways
- Tesamorelin and sermorelin are prescription‑only medicines. They are not for over‑the‑counter or grey‑market purchase.
- Availability may involve unapproved medicine pathways (e.g., SAS‑B or Authorised Prescriber) where clinically appropriate. Your prescriber will advise on eligibility and risks.
- Importing peptides without a valid pathway can lead to seizure and legal issues. Always use legitimate medical channels.
Read more: Is Tesamorelin Legal in Australia?, Is Sermorelin Legal in Australia?, Peptide Clinics Australia, Online Peptide Clinic Australia, Buy Peptides Australia.
Alternatives to discuss with your clinician
- CJC‑1295 and ipamorelin (alone or in combination) for GH‑axis support: What Is CJC‑1295?, What Is Ipamorelin?, CJC‑1295 vs Sermorelin, Ipamorelin vs Sermorelin, Tesamorelin vs Ipamorelin.
- GLP‑1 or dual‑agonist therapies for medically supervised weight loss: Semaglutide for Weight Loss, Tirzepatide for Weight Loss.
Frequently asked questions
Is tesamorelin better than sermorelin?
It depends on your goal. For clearly defined visceral abdominal fat, tesamorelin has targeted evidence. For broader GH support, clinicians may consider sermorelin with monitoring. Discuss your metrics and risks with a prescriber.
How long until results are noticed?
Tesamorelin trials assess VAT change over months, often 3–6 months. Sermorelin can raise IGF‑1 within weeks, but symptom changes vary person‑to‑person. See Tesamorelin Results Timeline and Sermorelin Results Timeline.
Can they be used together?
Combination protocols should only be considered under specialist care with clear objectives and IGF‑1 monitoring. Do not self‑combine.
Do they help general weight loss?
Tesamorelin targets visceral fat rather than broad weight loss. Sermorelin is not an approved weight loss therapy. For weight management, your doctor may discuss GLP‑1 options such as semaglutide or tirzepatide where eligible.
Are there side effects?
Yes. Both can cause injection site reactions and raise IGF‑1; tesamorelin can affect glucose tolerance. Review Tesamorelin Side Effects and Sermorelin Side Effects and speak with your clinician.
How are they taken?
Both are typically given as daily subcutaneous injections. Protocols vary. See Tesamorelin Dosage, Sermorelin Dosage and the Peptide Injection Guide.
What about Australian legality?
They are prescription‑only. Access may occur via unapproved medicine pathways where clinically justified. See Tesamorelin legal status and Sermorelin legal status.
Who should I see?
Start with a doctor experienced in peptide prescribing and metabolic or endocrine concerns. You can review Peptide Clinics Australia and Peptide Doctors Australia.
Get help deciding: speak with an Australian provider
Send your goals and background. A clinic can explain suitability, access pathways and monitoring based on your situation.
Information on this page is general in nature and does not replace personalised medical advice. Always speak with a qualified healthcare professional.
Bottom line
If your goal is specifically to reduce visceral abdominal fat under medical supervision, tesamorelin is the more targeted option with supporting trials. If your goal is broader GH‑axis support (sleep, recovery, body composition) with careful monitoring, sermorelin may be discussed with your clinician.